Stelexis Therapeutics
Zhuoxun Wu is a highly motivated scientist with experience in cancer pharmacology. Zhuoxun received his bachelor’s degree in China and earned his Ph.D. degree at St. John’s University where he studied the drug resistance mechanism of small molecule inhibitors and the strategies to overcome efflux transporter-mediated multidrug resistance. He joined Stelexis in June 2022 as a Research Scientist to work on the TumorOrigin™ platform team for drug discovery and development.
Stelexis Therapeutics
Stelexis is a Deerfield founded and solely funded New York-based cancer therapeutics company with a mission of transforming cancer therapeutics paradigm and patient care, through the discovery and development of novel drugs.